- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05628155
MAÏA - MAintain the Level of Independence Through Alimentation (MAÏA)
Malnutrition has serious consequences: increased risk of falls, hospitalization and mortality. Malnutrition may accompany or aggravate another geriatric syndrome. The loss of muscle mass and function, called "sarcopenia" can itself lead to a loss of physical activity and therefore of independence.
It has been reported that changes in the quantity or quality of food intake could influence the onset or progression of sarcopenia. Thus, an optimized oral diet covering the energy and protein needs of the elderly people living in a nursing home is a key element of the malnutrition prevention strategy. It could help slow down the loss of independence and have a direct impact on the occurrence of the complications mentioned above, and therefore on the use of care.
In the elderly, as in the general population, the consumption of linoleic acid (LA), precursor of the omega 6 line, is too high, and that of alpha-linolenic acid (ALA), precursor of the omega 3 line, insufficient. The French National Institute against Cancer (INCA) 3 survey results indicate for the 65-79 year old population average ALA intakes of 0.9 g/d whereas the recommendation is 2 g/d. The same is true for long-chain n-3 PUFAs (eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)).
There are currently no recommendations specifically concerning nursing home populations. Only recommendations for non-frail people, over the age of 65, exist (ANSES, 2019). Experts recommend maintaining or even slightly increasing the consumption of portions of meat, eggs, fish, fruits and vegetables and dairy products.
In the elderly, as in adults, an imbalance of n-6/n-3 PUFA intake or insufficient n-3 PUFA intake could facilitate the occurrence of cardiovascular diseases and certain cancers. The possible prevention of other pathologies more specific to the elderly, such as degenerative diseases, makes the consumption of n-3 PUFAs relevant in this population.
Our approach aiming to cover the recommended dietary allowances (RDA) of n-3 PUFAs via the oral diet is therefore very original.
An oral diet containing these different sources of fatty acid intake, of various origins, and other essential nutrients for the elderly, would have the advantage of meeting the nutritional objectives on the one hand, and of offering a wide range of tastes, flavors, and texture, allowing to optimize their consumption by nursing home residents, on the other hand. No study has yet evaluated the benefits of n-3 PUFA intake in dependent elderly people residing in nursing homes, moreover, using loss of independence as the main endpoint.
The main objective of the trial is to evaluate the effect of an everyday diet containing n-3 PUFA intakes corresponding to the RDA (population > 65 years) compared to the usual diet (therefore uncontrolled) on the evolution of the loss of independence at 2 years of nursing home residents.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prospective, controlled, randomized, multicentre, open-label clinical study comparing two groups of residents:
- "Control" group: nursing home residents will receive an oral diet covering their nutritional needs in macronutrients as recommended for people over 70-65 years of age.
- "Intervention" group: nursing home residents will receive an oral diet covering their nutritional needs in macronutrients as recommended for people over 65-70 years of age and including n-3 PUFA intake corresponding to the RDAs for people over 65 years.
Residents will be included in clusters corresponding to the nursing homes in which they reside.
The intervention will be delivered "at the nursing home level", i.e. all the residents included in the same nursing home will belong to the same "control" or "intervention" group.
Notes: Note that a randomization of residents across the individual residents was not possible from a logistical point of view in a context of collective feeding in an institution.
Actimetry analyzes as a marker of frailty. The investigators will conduct an ancillary study of actimetry analysis, on a sub-population of 60 residents (n=30 per group), in order to quantify physical activity and try to identify a possible trajectory of frailty that The investigators can correlate to the studied endpoints. To do this, the investigators will have a device consisting of an accelerometer and a barometer which will be positioned in a case around the neck (pendant) or failing that - if the resident expresses a preference - on the wrist (bracelet) to monitor participants' activities for 24 months. The nursing homes concerned will be selected for their proximity to Rennes and the homogeneity of the physical activities routinely offered to residents. The measures will be performed one week per month for 24 months.
Main judgment criterion: Measurement of the level of independence by the ADL-LFS (Activities of Daily Living - Long Form Score) at 2 years from the RAI-MDS 3.0 questionnaire (Resident Assessment Instrument Minimum Dataset) LTCF (Long-Term Care Facilities).
Secondary endpoints:
Evaluate the effect of an everyday diet containing n-3 PUFA intakes corresponding to the RDA (population > 65 years) compared to the usual diet (therefore uncontrolled) on the following endpoints:
- The evolution of anthropometric criteria and malnutrition
- The risk of falling
- The risk of an infection occurring
- The evolution of the quality of life
- Mortality
- Healthcare consumption (hospitalizations and visits to the emergency room)
In a sub-population of 60 residents (n=30 per group) randomly selected among the participants of a few volunteer nursing homes and meeting the inclusion and non-inclusion criteria of the study.
- The evolution of the quality of physical and sporting activity
- The evolution of the quality of sleep
Organic:
- The biological profile of blood fatty acids and concentrations of ALA, EPA, DPA, DHA in red blood cells
- Micro-CRP and albumin
- Evaluation of the cost of implementing the nutritional intervention from the perspective of nursing homes vs the clinical benefits
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ronan THIBAULT, MD, PhD
- Phone Number: 33 02.99.28.96.46
- Email: ronan.thibault@chu-rennes.fr
Study Contact Backup
- Name: Kristell COAT
- Phone Number: 33 0299282555
- Email: kristell.coat@chu-rennes.fr
Study Locations
-
-
-
Rennes, France, 35000
- Recruiting
- Les jardins d'Hermine
-
Contact:
- Natacha LAMIRE
-
Principal Investigator:
- Natacha LAMIRE
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Residents in permanent accommodation in participating nursing homes during the inclusion period;
- Residents in accommodation in nursing homes with similar catering services and who are not supplied with Bleu Blanc Coeur® food or who are supplied with at most 2 BBC products per week;
- Affiliation to a social security scheme;
- Consent signed by the resident or the person in charge of the representative
Exclusion Criteria:
- ADL-LFS score on inclusion >19;
- Exclusive enteral nutrition;
- Protection of effective justice;
- Lack of understanding of the French language;
- Estimated life expectancy of less than 12 months on inclusion, estimated by the attending physician or, if there is one, the nursing home physician.
- Only for the ancillary actimetry study: residents under guardianship or unable to self-manage.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
|
|
Experimental: Oral diet including n-3 PUFA intake
Oral diet covering the nutritional requirements in macronutrients as recommended for people over 65 years of age (ANSES, 2019) and including intakes of n-3 PUFAs corresponding to the recommendations for people over 65 years of age
|
menus to cover the recommended intake of n-3 PUFAs (ALA =1% of total energy intake, i.e. 2.1 g/d, and EPA+DHA = 500 mg/d) (n-3 PUFA MENU), based on mass-market products that guarantee the n-3 PUFA RDAs and are available from the catering sector
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
independence level
Time Frame: at 2 years
|
Measurement of independence level of by the ADL-LFS (Activities of Daily Living - Long Form Score) at 2 years.
The evaluation criterion used is the functional numerical scale from 0 to 28 (0 = independent, 28= total dependence)
|
at 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ronan THIBAULT, MD, PhD, Rennes University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 35RC21_9884_MAÏA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clinical Trial
-
Vanderbilt University Medical CenterNational Cancer Institute (NCI); Meharry-Vanderbilt AllianceCompleted
-
Universidade Estadual de Ponta GrossaCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.Completed
-
University Vila VelhaNot yet recruiting
-
Universidade Estadual de Ponta GrossaCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.Completed
-
Rana Ayman KamalUnknownRandomized Clinical Trial
-
Cairo UniversityUnknown
-
BayerCompleted
-
BayerCompleted
-
BayerCompletedClinical Trial, Phase IGermany
-
BayerCompletedPharmacokinetics | Clinical Trial, Phase INetherlands
Clinical Trials on Oral diet including n-3 PUFA intake
-
University Hospital, LilleTerminatedCystic Fibrosis | Dietary ModificationFrance
-
University of ReadingCompleted
-
University of JenaCompletedRheumatoid ArthritisGermany
-
University of JenaCompletedHypertriglyceridemiaGermany
-
Universidade Federal do Rio de JaneiroCompleted
-
Medical University of ViennaEnervit Spa (company)CompletedDiabetes | Overweight | Insulin Resistance | ObeseAustria
-
Haukeland University HospitalUniversity of Oslo; University of BergenCompletedCardiovascular Disease
-
University of JenaGerman Federal Ministry of Education and ResearchCompleted
-
Tehran University of Medical SciencesCompletedCardiovascular DiseaseIran, Islamic Republic of
-
Tehran University of Medical SciencesCompletedCardiovascular DiseaseIran, Islamic Republic of